Literature DB >> 32445579

Prognostic Value of C-Reactive Protein in Patients With Coronavirus 2019.

Xiaomin Luo1, Wei Zhou2, Xiaojie Yan1, Tangxi Guo1, Benchao Wang1, Hongxia Xia1, Lu Ye1, Jun Xiong1, Zongping Jiang1, Yu Liu1, Bicheng Zhang2, Weize Yang1.   

Abstract

BACKGROUND: An elevated serum C-reactive protein (CRP) level was observed in most patients with coronavirus disease 2019 (COVID-19).
METHODS: Data for COVID-19 patients with clinical outcome in a designated hospital in Wuhan, China, were retrospectively collected and analyzed from 30 January 2020 to 20 February 2020. The prognostic value of admission CRP was evaluated in patients with COVID-19.
RESULTS: Of 298 patients enrolled, 84 died and 214 recovered. Most nonsurvivors were male, older, or with chronic diseases. Compared with survivors, nonsurvivors showed significantly elevated white blood cell and neutrophil counts, neutrophil to lymphocyte ratio (NLR), systemic immune inflammation index (defined by platelet count multiplied by NLR), CRP, procalcitonin, and D-dimer and showed decreased red blood cell, lymphocyte, and platelet counts. Age, neutrophil count, platelet count, and CRP were identified as independent predictors of adverse outcome. The area under the receiver operating characteristic (ROC) curve (AUC) of CRP (0.896) was significantly higher than that of age (0.833), neutrophil count (0.820), and platelet count (0.678) in outcome prediction (all P < .05). With a cutoff value of 41.4, CRP exhibited sensitivity of 90.5%, specificity of 77.6%, positive predictive value of 61.3%, and negative predictive value of 95.4%. CRP was also an independent discriminator of severe/critical illness on admission with an AUC (0.783) comparable to age (0.828) and neutrophil count (0.729) (both P > .05).
CONCLUSIONS: In patients with COVID-19, admission CRP correlated with disease severity and tended to be a good predictor of adverse outcome.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  C-reactive protein; COVID-2019; SARS-CoV-2; prognosis

Mesh:

Substances:

Year:  2020        PMID: 32445579      PMCID: PMC7314209          DOI: 10.1093/cid/ciaa641

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  129 in total

1.  Predictive value of neutrophil-to-lymphocyte ratio and other inflammatory indicators in estimating clinical severity of coronavirus disease.

Authors:  Guang-Qing Yu; Qing Zhang; Run-Chang Wang; Shi-Qin Jiang
Journal:  World J Emerg Med       Date:  2021

Review 2.  The Role of Smoking and Nicotine in the Transmission and Pathogenesis of COVID-19.

Authors:  Ali Ehsan Sifat; Saeideh Nozohouri; Heidi Villalba; Bhuvaneshwar Vaidya; Thomas J Abbruscato
Journal:  J Pharmacol Exp Ther       Date:  2020-10-08       Impact factor: 4.030

3.  Insights into the Immunopathophysiology of Severe COVID-19 in Metabolic Disorders.

Authors:  Skand Shekhar; Caroline E Copacino; Francisco J Barrera; Janet E Hall; Fady Hannah-Shmouni
Journal:  Ann Natl Acad Med Sci       Date:  2020-04

4.  C-reactive protein as an early predictor of COVID-19 severity.

Authors:  Maryame Ahnach; Saad Zbiri; Sara Nejjari; Fadwa Ousti; Chafik Elkettani
Journal:  J Med Biochem       Date:  2020-10-02       Impact factor: 3.402

5.  Biochemistry tests in hospitalized COVID-19 patients: Experience from a canadian tertiary care centre.

Authors:  Angela C Rutledge; Yun-Hee Choi; Igor Karp; Vipin Bhayana; Ivan Stevic
Journal:  Clin Biochem       Date:  2021-05-19       Impact factor: 3.281

6.  A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic.

Authors:  Hyung-Jun Kim; Hyeontaek Hwang; Hyunsook Hong; Jae-Joon Yim; Jinwoo Lee
Journal:  Sci Rep       Date:  2021-05-07       Impact factor: 4.379

7.  Extracorporeal Blood Purification in Moderate and Severe COVID-19 Patients: A Prospective Cohort Study.

Authors:  Rodney Alexander Rosalia; Petar Ugurov; Dashurie Neziri; Simona Despotovska; Emilija Kostoska; Lidija Veljanovska-Kiridjievska; Dimche Kuzmanov; Aleksandar Trifunovski; Dijana Popevski; Gianluca Villa; Zan Mitrev
Journal:  Blood Purif       Date:  2021-06-14       Impact factor: 2.614

8.  Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

Authors:  Clark D Russell; Cameron J Fairfield; Thomas M Drake; Lance Turtle; R Andrew Seaton; Dan G Wootton; Louise Sigfrid; Ewen M Harrison; Annemarie B Docherty; Thushan I de Silva; Conor Egan; Riinu Pius; Hayley E Hardwick; Laura Merson; Michelle Girvan; Jake Dunning; Jonathan S Nguyen-Van-Tam; Peter J M Openshaw; J Kenneth Baillie; Malcolm G Semple; Antonia Ho
Journal:  Lancet Microbe       Date:  2021-06-02

9.  Use of Procalcitonin during the First Wave of COVID-19 in the Acute NHS Hospitals: A Retrospective Observational Study.

Authors:  Neil Powell; Philip Howard; Martin J Llewelyn; Tamas Szakmany; Mahableswhar Albur; Stuart E Bond; Joanne Euden; Lucy Brookes-Howell; Paul Dark; Thomas P Hellyer; Susan Hopkins; Iain J McCullagh; Margaret Ogden; Philip Pallmann; Helena Parsons; David G Partridge; Dominick E Shaw; Bethany Shinkins; Stacy Todd; Emma Thomas-Jones; Robert West; Enitan D Carrol; Jonathan A T Sandoe
Journal:  Antibiotics (Basel)       Date:  2021-05-01

10.  Diagnosis of COVID-19 by exhaled breath analysis using gas chromatography-mass spectrometry.

Authors:  Wadah Ibrahim; Rebecca L Cordell; Michael J Wilde; Matthew Richardson; Liesl Carr; Ananga Sundari Devi Dasi; Beverley Hargadon; Robert C Free; Paul S Monks; Christopher E Brightling; Neil J Greening; Salman Siddiqui
Journal:  ERJ Open Res       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.